Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On 18F-FDG PET/CT at Baseline

被引：1

作者：

Cho, Hee Jeong ^{[1
]}

Baek, Dong Won ^{[1
]}

Kim, Ju-Hyung ^{[1
]}

Lee, Jungmin ^{[1
]}

Chung, Yu Kyung ^{[2
]}

Jung, Sung-Hoon ^{[3
]}

Song, Ga-Young ^{[3
]}

Ahn, Seo-Yeon ^{[3
]}

Ahn, Jae-Sook ^{[3
]}

Yang, Deok-Hwan ^{[3
]}

Lee, Je-Jung ^{[3
]}

Kim, Hyeoung-Joon ^{[3
]}

Hong, Chae Moon ^{[4
]}

Jeong, Shin Young ^{[4
]}

Min, Jung-Joon ^{[5
]}

Sohn, Sang-Kyun ^{[1
]}

Moon, Joon Ho ^{[1
]}

机构：

[1] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, 130 Dongdeok Ro, Daegu 41944, South Korea

[2] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, Daegu, South Korea

[3] Chonnam Natl Univ, Dept Hematol Oncol, Hwasun Hosp, Hwasun, Jeollanamdo, South Korea

[4] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Nucl Med, Daegu, South Korea

[5] Chonnam Natl Univ, Dept Nucl Med, Hwasun Hosp, Hwasun, South Korea

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷 / 02期

关键词：

Newly diagnosed multiple myeloma; 18F-FDG PET/CT; Focal lesions; Autologous stem cell transplantation; Long-term outcomes; POSITRON-EMISSION-TOMOGRAPHY; EXTRAMEDULLARY DISEASE; BONE-DISEASE; CONSENSUS; LENALIDOMIDE; CHEMOTHERAPY; EXPRESSION; DIAGNOSIS; CRITERIA; IMPACT;

D O I：

10.1016/j.clml.2021.08.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To evaluate the role of autologous stem cell transplantation (ASCT) in multiple myeloma patients with a number of focal lesions (FL) >3 on baseline positron emission tomography/computed tomography (PET/CT), we analyzed the medical records of 210 patients. The results showed that patients with FL >3 receiving upfront ASCT have improved survival outcomes compared to those not receiving ASCT. Background: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (F-18-FDG PET/CT) is a useful tool for identifying high-risk features in patients with newly diagnosed multiple myeloma (NDMM). This study evaluated the role of autologous stem cell transplantation (ASCT) in patients presenting with positive results on PET/CT scans. Materials and Methods: The medical records of 210 patients who underwent PET/CT at diagnosis were retrospectively reviewed. Eligible patients for transplantation proceeded to upfront ASCT with high-dose chemotherapy (HDT) after induction therapy with novel agents. Results: The presence of a number of focal lesions (FL) >3 and extramedullary disease (EMD) occurred in 111 and 35 patients, respectively. ASCT was performed in 54 patients. Among patients with FL > 3, those treated with ASCT showed a prolonged 2-year progression-free survival (PFS) and overall survival (OS) rates compared to those not treated with ASCT (PFS, 60.2% vs. 23.5%, P < 0.001; OS, 91.7% vs. 63.6%, P = 0.005). In patients with FL <= 3, treatment by ASCT was associated with a higher 2-year PFS rate than no treatment by ASCT (74.0% vs. 54.9%, P = 0.040). The OS of patients treated with ASCT was not significantly longer than that of patients not treated with ASCT (P = 0.115). In multivariate analysis, FL > 3, Revised International Staging System (R-ISS), and upfront ASCT were independent prognostic factors for PFS and OS. Conclusion: Presenting FL > 3 on baseline PET/CT represents a high-risk feature in patients with NDMM. Frontline ASCT with HDT prolonged the survival of patients with FL > 3. (C) 2021 Elsevier Inc. All rights reserved.

引用

页码：113 / 120

页数：8

共 30 条

[1] Current status of autologous stem cell transplantation for multiple myeloma [J].

Al Hamed, Rama ;

Bazarbachi, Abdul Hamid ;

Malard, Florent ;

Harousseau, Jean-Luc ;

Mohty, Mohamad .

BLOOD CANCER JOURNAL, 2019, 9 (4)

[2] Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma [J].

Attal, Michel ;

Lauwers-Cances, Valerie ;

Hulin, Cyrille ;

Leleu, Xavier ;

Caillot, Denis ;

Escoffre, Martine ;

Arnulf, Bertrand ;

Macro, Margaret ;

Belhadj, Karim ;

Garderet, Laurent ;

Roussel, Murielle ;

Payen, Catherine ;

Mathiot, Claire ;

Fermand, Jean P. ;

Meuleman, Nathalie ;

Rollet, Sandrine ;

Maglio, Michelle E. ;

Zeytoonjian, Andrea A. ;

Weller, Edie A. ;

Munshi, Nikhil ;

Anderson, Kenneth C. ;

Richardson, Paul G. ;

Facon, Thierry ;

Avet-Loiseau, Herve ;

Harousseau, Jean-Luc ;

Moreau, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14) :1311-1320

[3] F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma [J].

Bartel, Twyla B. ;

Haessler, Jeff ;

Brown, Tracy L. Y. ;

Shaughnessy, John D., Jr. ;

van Rhee, Frits ;

Anaissie, Elias ;

Alpe, Terri ;

Angtuaco, Edgardo ;

Walker, Ronald ;

Epstein, Joshua ;

Crowley, John ;

Barlogie, Bart .

BLOOD, 2009, 114 (10) :2068-2076

[4]

Beksac M, 2014, IMPACT PET CT RESPON

[5] Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach [J].

Blade, Joan ;

Fernandez de Larrea, Carlos ;

Rosinol, Laura ;

Teresa Cibeira, Maria ;

Jimenez, Raquel ;

Powles, Ray .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (28) :3805-3812

[6]

Cavo M, 2016, UPFRONT AUTOLOGOUS S

[7]

Cavo M, 2016, INTENSIFICATION THER

[8] Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group [J].

Cavo, Michele ;

Terpos, Evangelos ;

Nanni, Cristina ;

Moreau, Philippe ;

Lentzsch, Suzanne ;

Zweegman, Sonja ;

Hillengass, Jens ;

Engelhardt, Monika ;

Usmani, Saad Z. ;

Vesole, David H. ;

San-Miguel, Jesus ;

Kumar, Shaji K. ;

Richardson, Paul G. ;

Mikhael, Joseph R. ;

da Costa, Fernando Leal ;

Dimopoulos, Meletios-Athanassios ;

Zingaretti, Chiara ;

Abildgaard, Niels ;

Goldschmidt, Hartmut ;

Orlowski, Robert Z. ;

Chng, Wee Joo ;

Einsele, Hermann ;

Lonial, Sagar ;

Barlogie, Bart ;

Anderson, Kenneth C. ;

Rajkumar, S. Vincent ;

Durie, Brian G. M. ;

Zamagni, Elena .

LANCET ONCOLOGY, 2017, 18 (04) :E206-E217

[9] High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma [J].

Child, JA ;

Morgan, GJ ;

Davies, FE ;

Owen, RG ;

Bell, SE ;

Hawkins, K ;

Brown, J ;

Drayson, MT ;

Selby, PJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (19) :1875-1883

[10] Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial [J].

Gay, Francesca ;

Oliva, Stefania ;

Petrucci, Maria Teresa ;

Conticello, Concetta ;

Catalano, Lucio ;

Corradini, Paolo ;

Siniscalchi, Agostina ;

Magarotto, Valeria ;

Pour, Ludek ;

Carella, Angelo ;

Malfitano, Alessandra ;

Petro, Daniela ;

Evangelista, Andrea ;

Spada, Stefano ;

Pescosta, Norbert ;

Omede, Paola ;

Campbell, Philip ;

Liberati, Anna Marina ;

Offidani, Massimo ;

Ria, Roberto ;

Pulini, Stefano ;

Patriarca, Francesca ;

Hajek, Roman ;

Spencer, Andrew ;

Boccadoro, Mario ;

Palumbo, Antonio .

LANCET ONCOLOGY, 2015, 16 (16) :1617-1629

← 1 2 3 →